OT mobile menu



New Targets, Therapy Combinations in Breast Cancer

Large breast cancer study reveals new uses for existing drugs, along with new drug combinations and targets. Image © iQoncept/ Shutterstock.com

Recent Content

Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.

The majority of renal cell carcinomas harbor VHL tumor-suppressor gene deletions that cause tumor addiction to extracellular cystine—and cystine deprivation triggers tumor cell necrosis.

Dr. Marachelian and her team have demonstrated that there is a new treatment that is equivalent to a product that has been manufactured for commercial use and should be made available to patients outside of clinical trials.

The PD-1‒targeting drug nivolumab combined with stereotactic radiation may work synergistically and help improve overall survival while resulting in minimal neurotoxicity in brain metastatic melanoma patients.

Nivolumab (Opdivo) demonstrated superior overall survival (OS) among patients diagnosed with metastatic, platinum-refractory head and neck squamous cell carcinoma.

Second-generation, EGFR-directed therapy afatinib (Gilotrif) may be superior to first-generation gefitinib (Iressa) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive, advanced non-small cell lung cancer.

Somatic immune system gene variants predict the survival time of patients with cutaneous melanoma, and might augment existing clinical and pathologic prognostic tools, report researchers at New York University’s Langone Medical Center and Perlmutter Cancer Center.

By clicking Accept, you agree to become a member of the UBM Medica Community.